An exciting milestone for portfolio company Enterprise Therapeutics, which has today announced the dosing of the first person with cystic fibrosis (pwCF) in its Phase 2a trial of ETD001. Read more: https://bit.ly/4bUuhbx #CysticFibrosis #ClinicalTrial
About us
IP Group accelerates the impact of science for a better future. As the most active UK based, early-stage science investor, we develop and support some of the world’s most exciting businesses in deeptech, life sciences and cleantech (led by Kiko Ventures). Through Parkwalk, the UK's largest growth EIS fund manager, we also back world-changing innovation emerging in leading universities and research institutions. Our specialist investment team combines sector expertise with an international approach. Together we have a strong track record of success, having backed high-profile companies including Oxford Nanopore Technologies plc, First Light Fusion, Hysata, and Oxbotica. IP Group is listed on the Main Market of the London Stock Exchange under the code IPO.
- Website
-
http://www.ipgroupplc.com
External link for IP Group plc
- Industry
- Financial Services
- Company size
- 51-200 employees
- Headquarters
- London, England
- Type
- Public Company
Locations
Employees at IP Group plc
Updates
-
Take a read of this op-ed from Mike Molinari, Managing Director at IP Group Australia, which highlights the importance of the Strategic Examination of R&D that was announced in the recent federal budget for Australia’s future productivity and competitiveness. Originally published in The Australian, Mike encourages the review to take a broad and bold focus to ensure that Australia remains competitive in an increasingly innovative world. 👉 https://bit.ly/46hpSOv
-
Some great news from portfolio company Abliva AB, who yesterday announced positive interim analysis of their Phase 2 trial. Ellen Donnelly, Chief Executive Officer of Abliva said “We are pleased with the positive outcome of the interim analysis as it highlights the positive risk-benefit of KL1333, de-risking the full study, increasing our confidence in KL1333’s novel mechanism of action and the FALCON study design.” “There are currently no approved therapies for mitochondrial disease and with over 85,000 people affected across the US and Europe, we believe KL1333 is well-positioned to address this high unmet medical need and reach blockbuster potential in key geographies. KL1333 has the potential for an expedited path to market and we are committed to rapidly advancing this important medicine towards approval, with plans to start the final wave of FALCON study recruitment in the second half of 2024.” Read the full press release here: https://bit.ly/3WwLcww #MitochondrialDisease #ClinicalTrials #KL1333
-
💡Energy use in data centres while running AI models has been a big topic of discussion at IP Group plc lately! Not only at our recent deeptech event, but in this recent Insight piece from Dr Lee Thornton (https://bit.ly/4bGSvFT). Adding to the conversation, Phillip Burr (Head of Product at our portfolio company Lumai) explores how optical interconnects and processing can positively transform data centres. These technologies play a significant role in enhancing energy efficiency and performance, especially in the face of growing demands for data and AI. 👇Read below #AI #Optics #DataCentres
-
Great news from portfolio company Intelligent Ultrasound, which today announced the proposed sale of its Clinical AI business to GE HealthCare for £40.5m. Achieving a premium of 70.9% to its closing share price yesterday for that business unit alone, is a great outcome for the company. Furthermore, Intelligent Ultrasound will retain its simulation business, which generated total revenues of £10m in 2023. Intelligent Ultrasound also noted that it intends to make a material return of capital following a review of the growth potential and capital requirements of the post-transaction business. IP Group plc has an undiluted beneficial holding of 20.8% in Intelligent Ultrasound. In addition, our EIS fund management business, Parkwalk Advisors, holds 11.0% of Intelligent Ultrasound. Read more: https://bit.ly/4bO9shN #Ultrasound #Innovation
-
💡The latest edition of the IP Group plc newsletter is now available to read. Featuring news from the Group and portfolio companies including Garrison, Mission Therapeutics and Mixergy Ltd. Read here: https://bit.ly/3S785ny Sign up to receive our newsletter here: https://bit.ly/3WnGFfN #BackingInnovation
-
Today marks World Youth Skills Day, a day dedicated to celebrating the importance of equipping young individuals with the skills necessary for employment and entrepreneurship. At IP Group plc, we understand the significance of ensuring that the next generation is given opportunities to gain real-world experience and every summer we are incredibly privileged to have the presence of several talented interns among us. Thanks to our partnership with the 10,000 Black Interns program - an initiative which we have supported since its inception in 2020 - Cameron Cline-Cole has joined our IP Capital team to work on to research changes and indicators within UK capital markets and support corporate finance advisory engagements. We also have Priscille Nlele joining later this month to work within our Deeptech team. Last week we also welcomed Evelyn Ogbomo, Harris Majid, Lila camara, Sammy Hilfawi, Tobi Abebiosu and Yasar Alam from the Big City Bright Future work experience programme organised by our charity partner IntoUniversity, which assigned them to IP Group based on their individual interests and aspirations in STEM subjects. We have been honoured to have taken part in the BCBF programme since 2021 and are passionate about helping to provide 6th Form students with experiences that will help them to both plan and get the most out of Higher Education. On this #WorldYouthSkillsDay, let us come together and acknowledge the tremendous potential of young people as catalysts for change.
-
Last week we were thrilled to host our Deeptech focused event and panel discussion “AI Investing in a post-LLM world. Where next for the UK Deeptech venture community?” This provided for thought provoking conversations around the Deeptech investment landscape, emerging trends and market insights relating to the use of AI in general and LLMs (large language models) in particular. Read more about the opportunities and challenges posed by the worldwide explosion in the development and use of Artificial Intelligence in this insight piece from Dr Lee Thornton, Technology Partner at IP Group plc, in which he explores how compute can continue to meet the exponential growth in demand without draining the world’s energy supply. With existing technology reaching its limit, how might the internet find ways to accommodate cutting-edge AI in the future? And where do we see some of our portfolio companies, including Lumai, and Deep Render, having an impact? 👉 https://bit.ly/4bGSvFT #Deeptech #AI #LLM
-
Last night we had the pleasure of hosting our latest Deeptech focused event at our London office: “AI Investing in a post-LLM world. Where next for the UK Deeptech venture community?” The evening saw Dr Lee Thornton, Technology Partner at IP Group plc moderate a panel of industry experts Dr Adnan Mehonic (Co-Founder and CTO at Intrinsic Semiconductor Technologies), Kevin Crain (CTO of Intel Ignite London) and Dr Peter Schrammel (CTO and Co-Founder of Diffblue). This was a fascinating and insightful discussion, which covered topics including: 💡 The investment landscape How to deploy capital into early stage deeptech companies in a world where the competition is a £3tn company. 💡Looking forward The fragmentation of the market away from CPUs to GPUs, analogue computing, quantum, post-von Neumann and the opportunities this presents. 💡Emerging trends The demand for energy in training models is ever present as a factor in their build, but do we need to focus more on inference, especially at the edge? And what comes after LLMs? They are but language models, not search engines, so how can they evolve into something more consequential and reliable! 💡Market insights Chatbots are viewed as being the biggest, nearest term target for implementation for LLMs which will make a real impact in people’s lives, but there are plenty of other opportunities which will come about, a lot of which are currently unknown. Thank you to our panellists and attendees for making this event a success and a thoroughly enjoyable evening. #AI #AIInvesting #Deeptech
-
📢 Amazing news that The Michael J. Fox Foundation for Parkinson's Research and Parkinson's UK have awarded $5.2m to portfolio company Mission Therapeutics. The funds will help Mission expand the Phase 1 study on MTX325, its potential disease-modifying treatment for Parkinson’s disease, into early-stage patients. 👉 Read more here: https://bit.ly/3VR5xe6 #ParkinsonsDisease